Clearing and replacing tissue-resident myeloid cells with an anti-CD45 antibody–drug conjugate

Tissue-resident myeloid (TRM) cells in adults have highly variable lifespans, and may be derived from early embryonic yolk sac, fetal liver, or bone marrow. Some of these TRM cells are known pathogenic participants in congenital and acquired diseases. Myeloablative conditioning and hematopoietic ste...

Descripción completa

Detalles Bibliográficos
Autores principales: Gustafsson, Karin, Rhee, Catherine, Frodermann, Vanessa, Scadden, Elizabeth W., Li, Dan, Iwamoto, Yoshiko, Palchaudhuri, Rahul, Hyzy, Sharon L., Boitano, Anthony E., Nahrendorf, Matthias, Scadden, David T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Hematopoiesis and Stem Cells
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690556/
https://www.ncbi.nlm.nih.gov/pubmed/37748049
http://dx.doi.org/10.1182/bloodadvances.2023010561

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690556/
https://www.ncbi.nlm.nih.gov/pubmed/37748049
http://dx.doi.org/10.1182/bloodadvances.2023010561

Ejemplares similares